IGF-1 LR3 (1 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency is one subcutaneous injection per day for the length of the cycle, typically in the morning or post workout and taken with food to mitigate the insulin-like effect on blood glucose. At 1 mg/mL every step in this protocol is a very small draw, 2 to 5 units or 0.02 to 0.05 mL, so a 30 unit or 50 unit U-100 barrel is easier to read accurately than a 100 unit barrel; the same applies to any administration of 10 units (0.10 mL) or less. Injection sites are rotated systematically between the abdomen, outer thighs, and upper arms to avoid lipohypertrophy. Dose escalation is the period that warrants the closest attention to glucose related symptoms, which is why the titration steps sit at 2 weeks each before the 50 mcg ceiling is held. Cycling matters as much as the daily dose: continuous use beyond 6 to 8 weeks may bring diminished response through receptor desensitization, so the common structure is 8 weeks on followed by 4 to 8 weeks off.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: titration at 20 mcg daily, 2 units, the entry step where tolerance and glucose response are established.
• Weeks 3 to 4: step up to 40 mcg daily, 4 units, provided the first step was tolerated.
• Weeks 5 to 8: hold at 50 mcg daily, 5 units, the conservative ceiling for this protocol.
• Weeks 9 to 12: optional extension at the same 50 mcg daily ceiling, only where off periods are planned around it.
• After the cycle: 4 to 8 weeks off before repeating, since response falls off with continuous use beyond 6 to 8 weeks.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution (do not shake).
4. Use within 30 days of reconstitution; for longer storage, prepare sterile aliquots and freeze at minus 20 °C for up to 3 to 6 months.
5. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 1 mg/mL, 1 unit = 0.01 mL » 10 mcg on a U-100 insulin syringe, so 20 mcg is 2 units, 40 mcg is 4 units, and 50 mcg is 5 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C or colder in dry, dark conditions for up to 12 months; short term storage at 2 to 8 °C for several months is acceptable.
• Reconstituted: refrigerate at 2 to 8 °C immediately after mixing and use within 30 days for optimal potency. For extended storage, prepare sterile aliquots and freeze at minus 20 °C, where they remain stable for 3 to 6 months; never refreeze a thawed vial.

• Allow frozen vials to reach room temperature before opening to minimize condensation, then inspect the solution for clarity and discard it if it is cloudy or contains particles.
• Keep all vials protected from light and maintain cold chain throughout storage and transport.

Supplies Needed

Planning math is based on the standard 8 week daily cycle with gradual titration, which runs 140 mcg per week in weeks 1 to 2, 280 mcg per week in weeks 3 to 4, and 350 mcg per week in weeks 5 to 8.

Peptide Vials (IGF-1 LR3, 1 mg vial):

• An 8 week cycle totals about 2.24 mg, roughly 3 vials of 1 mg each; 12 weeks totals about 3.64 mg, roughly 4 vials, and 16 weeks totals about 5.04 mg, roughly 6 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per day, with a 30 unit or 50 unit barrel preferred for readability at draws of 2 to 5 units.
• Full cycle: 56 syringes over 8 weeks, 84 over 12 weeks, and 112 over 16 weeks.

Bacteriostatic Water (10 mL bottles):

• At 1.0 mL per 1 mg vial, one 10 mL bottle of bacteriostatic water covers 10 vials, so a single bottle carries the roughly 3 vials of an 8 week cycle and still covers the roughly 6 vials of a 16 week run.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin, which comes to 14 per week.
• Full cycle: 112 swabs over 8 weeks and 224 over 16 weeks, which is 2 to 3 boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Sterile technique: a new sterile insulin syringe for every injection, disposed of immediately in a sharps container. Sites are rotated systematically between abdomen, outer thighs, and upper arms.
• Hypoglycemia awareness: the insulin-like action on blood glucose is the defining practical risk here. Shakiness, dizziness, confusion, or sweating are the warning signs, and they are most likely during dose escalation, so a fast-acting carbohydrate source such as glucose tablets or juice belongs within reach for the whole cycle.
• Timing with meals: dosing with or shortly after food intake blunts the insulin-like effect on blood glucose and is the reason morning or post workout administration is the common choice.
• Documentation: a daily log of dose, injection site, and any observed effects is what makes a titration decision defensible rather than a guess.
• Never exceed conservative dosing: doses above 50 to 60 mcg per day lack robust clinical research support and may substantially increase adverse effect risk. Periodic blood glucose checks during titration are a reasonable precaution.
• Regulatory Note: IGF-1 LR3 has never received FDA approval or any other regulatory approval for human therapeutic use and remains restricted to research applications. It is not for human consumption. The anti-doping literature cited below covers dedicated assays for detecting LongR3-IGF-I and related analogs, so it is a substance actively screened for in tested sport.

How This Works

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension of 13 amino acids and a glutamic acid substitution at position 3, which together sharply reduce its binding affinity for IGF binding proteins. That single change is what the whole protocol rests on: native IGF-1 is captured by binding proteins and cleared within minutes, while the LR3 variant circulates freely and carries a half-life of several hours with substantially higher systemic bioavailability. The longer circulation time is what makes a once daily administration schedule workable in research settings and keeps plasma levels more stable across the day than native IGF-1, which would require frequent repeat dosing. Downstream activity is anabolic and metabolic and runs through IGF-1 receptor binding in target tissues. The same receptor family overlap that produces those effects also produces insulin-like action on blood glucose, which is why meal timing and glucose awareness are built into the dosing schedule rather than treated as optional, and why the titration and glucose caution weigh heaviest during the initial dosing and escalation phases. The compound has never been approved for therapeutic human use and remains confined to research applications.

Benefits & Side Effects

Observations from the published record.

• Enhanced anabolic signaling and protein synthesis in target tissues through IGF-1 receptor binding.
• Extended bioavailability compared with native IGF-1, the direct result of reduced binding protein interaction, alongside metabolic effects through the same IGF-1 receptor pathways.
• Hypoglycemia risk is the most significant concern with IGF-1 LR3, driven by its insulin-like effect on blood glucose. Symptoms may include shakiness, confusion, sweating, or dizziness, which is why administration with food and monitoring for glucose related symptoms are standard.
• Injection site reactions: mild local irritation, redness, or discomfort may occur.
• Dose-dependent effects: safety concerns increase substantially at doses exceeding 50 to 60 mcg per day, and conservative dosing is strongly recommended.
• Receptor desensitization: continuous use beyond 6 to 8 weeks may lead to diminished response, which is why cycling protocols of 8 weeks on and 4 to 8 weeks off are commonly employed. No FDA approval exists for human therapeutic use.

Lifestyle Factors

Complementary strategies for best outcomes.

• Nutrition: adequate protein intake in the range of 1.6 to 2.2 g per kg of body weight, with regular meal timing to keep blood glucose stable across the dosing window.
• Training: resistance training paired with adequate recovery, since IGF-1 signaling pathways are activated by mechanical loading and the peptide amplifies a signal that training has to supply.
• Sleep and recovery: 7 to 9 hours of quality sleep nightly supports endogenous growth factor production.
• Hydration and glucose tracking: consistent hydration supports metabolic function and peptide distribution, and periodic blood glucose checks during dose titration catch drift early.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports (Biomolecules / MDPI).
2. Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1): Medical information (Dopinglinkki / FINCIS).
3. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I for anti-doping purposes (Drug Testing and Analysis).
4. Mecasermin (Subcutaneous): proper use, dosing, and hypoglycemia management (Mayo Clinic / Drugs.com).